The FDA has approved an extended-release version of the GLP-1 drug exenatide for older children and teenagers with Type 2 diabetes, Andrew Briskin report for DiaTribe. BYDUREON BCise is a once-weekly injection that can help people manage their glucose levels together with changes in their lifestyle, such as diet and exercise. It has been approved in the US for adults with Type 2 diabetes for over 15 years old.
Recently published data showed worryingly high rates and serious diabetes complications in people who develop Type 2 diabetes at a young age, suggesting the need for aggressive early treatment and more treatment options. The approval comes after a clinical trial – BCB114 – examined the drug’s safety in 10–17-year-olds. Results showed a 0.4 percentage point decrease in HbA1C when using BYDUREON BCise, compared to a 0.5 percentage point increase in HbA1C among those taking the placebo drug.
To read the article in full CLICK HERE.
